This is the protocol for a review and there is no abstract. The objectives are as follows:, To evaluate the effectiveness and safety of anticoagulant thromboprophylaxis in reducing VTE events in cancer patients with CVL. We will assess all anticoagulants approved for clinical use. There are currently five anticoagulants available: unfractionated heparin (UFH), low molecular weight heparin (LMWH), vitamin K antagonists (VKA), fondaparinux and ximelagatran